Autolus Therapeutics plc - American Depositary Share (AUTL): Price and Financial Metrics


Autolus Therapeutics plc - American Depositary Share (AUTL): $5.61

0.03 (+0.54%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AUTL to Watchlist
Sign Up

Industry: Biotech


Ranked

of 508

in industry

AUTL POWR Grades


  • Sentiment is the dimension where AUTL ranks best; there it ranks ahead of 73.78% of US stocks.
  • AUTL's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
  • AUTL's current lowest rank is in the Momentum metric (where it is better than 4.46% of US stocks).

AUTL Stock Summary

  • AUTL's price/sales ratio is 97.95; that's higher than the P/S ratio of 96.49% of US stocks.
  • As for revenue growth, note that AUTL's revenue has grown 142.36% over the past 12 months; that beats the revenue growth of 95.13% of US companies in our set.
  • Autolus Therapeutics plc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -46.75%, greater than the shareholder yield of merely 6% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Autolus Therapeutics plc, a group of peers worth examining would be VBLT, ORGS, XCUR, ACIU, and CBIO.
  • Visit AUTL's SEC page to see the company's official filings. To visit the company's web site, go to www.autolus.com.

AUTL Valuation Summary

  • AUTL's price/sales ratio is 119.9; this is 956.39% higher than that of the median Healthcare stock.
  • Over the past 39 months, AUTL's price/sales ratio has gone down 437.9.
  • Over the past 39 months, AUTL's price/sales ratio has gone down 437.9.

Below are key valuation metrics over time for AUTL.

Stock Date P/S P/B P/E EV/EBIT
AUTL 2021-08-31 119.9 1.3 -2.5 -1.0
AUTL 2021-08-30 119.4 1.3 -2.4 -1.0
AUTL 2021-08-27 118.5 1.3 -2.4 -0.9
AUTL 2021-08-26 115.2 1.2 -2.4 -0.9
AUTL 2021-08-25 114.4 1.2 -2.3 -0.9
AUTL 2021-08-24 110.0 1.2 -2.2 -0.8

AUTL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AUTL has a Quality Grade of D, ranking ahead of 5.33% of graded US stocks.
  • AUTL's asset turnover comes in at 0.009 -- ranking 396th of 680 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows AUTL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.009 1 -1.295
2021-03-31 0.005 1 -1.315
2020-12-31 0.005 1 -1.295
2020-09-30 0.005 1 -1.458
2020-06-30 0.004 1 -1.587
2020-03-31 0.004 1 -1.568

AUTL Stock Price Chart Interactive Chart >

Price chart for AUTL

AUTL Price/Volume Stats

Current price $5.61 52-week high $12.28
Prev. close $5.58 52-week low $4.60
Day low $5.57 Volume 203,100
Day high $5.73 Avg. volume 1,107,485
50-day MA $6.37 Dividend yield N/A
200-day MA $6.52 Market Cap 408.09M

Autolus Therapeutics plc - American Depositary Share (AUTL) Company Bio


Autolus Therapeutics is developing a pipeline of advanced programmable T cell treatment candidates for blood and solid tumor cancers. Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I), or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma. The company is based in London, England.


AUTL Latest News Stream


Event/Time News Detail
Loading, please wait...

AUTL Latest Social Stream


Loading social stream, please wait...

View Full AUTL Social Stream

Latest AUTL News From Around the Web

Below are the latest news stories about Autolus Therapeutics plc that investors may wish to consider to help them evaluate AUTL as an investment opportunity.

Autolus Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3

LONDON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2021 financial results and operational highlights before open of U.S. markets on Wednesday, November 3, 2021. Management will host a conference call and webcast at 8:30 am ET/1:30 pm GMT to discuss the company’s financial results and provide a general business up

Yahoo | October 25, 2021

Autolus Therapeutics (NASDAQ:AUTL) shareholders have endured a 76% loss from investing in the stock three years ago

As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the...

Yahoo | October 4, 2021

Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK

- Allowing global commercial launch capacity for obe-cel (AUTO1)LONDON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that planning approval has been granted to build the Company’s new manufacturing facility in Stevenage, UK. The 70,000 square foot facility is being built by Merit Holdings Limited as general contractor for the Reef Group, who will lease

Yahoo | September 16, 2021

Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors

LONDON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that John H. Johnson has been appointed as non-executive chairman of its Board of Directors, effective September 15, 2021. Dr. Martin Murphy, who previously served as chairman, will continue to serve as a non-executive Board member. Mr. Johnson brings to Autolus more than 30 years of experience in th

Yahoo | September 15, 2021

Autolus Therapeutics to participate in upcoming virtual investor conferences

- Goldman Sachs Eleventh Annual Biotech Symposium on September 7- 2021 Virtual Wells Fargo Healthcare Conference on September 10 at 7.30am ET - H.C. Wainwright & Co 23rd Annual Global Investment Conference on September 13, at 7.00am ET LONDON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in three upcoming virtual invest

Yahoo | September 2, 2021

Read More 'AUTL' Stories Here

AUTL Price Returns

1-mo -10.81%
3-mo 2.37%
6-mo -1.58%
1-year -49.87%
3-year -80.66%
5-year N/A
YTD -37.25%
2020 -32.27%
2019 -59.81%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7578 seconds.